ENZ logo

Enzo Biochem (ENZ) Accounts Receivable

Annual Accounts Receivable

$3.99 M
-$820.00 K-17.05%

July 31, 2024

Summary

Performance

1-Year Change

-17.05%

3-Year Change

-60.89%

5-Year Change

-62.86%

15-Year Change

-73.73%

ENZ Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

37.59%
ENZ annual accounts receivable is higher than 37.59% of companies in Healthcare sector

High & Low

All-time High

$24.56 M
ENZ annual accounts receivable is currently -83.76% below its historical high of $24.56 million

3-Year Low

$3.99 M
ENZ annual accounts receivable is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Jul 31, 2024
ENZ previous annual earnings announcement was published on Jul 31, 2024

Next Annual Earnings Report Date

N/A
ENZ next annual earnings announcement has not yet been scheduled

OtherENZbalance sheetmetrics:

Annual Accounts Payable

$1.38 M
ENZ annual accounts payable is $1.38 million

Annual Total Assets

$85.76 M
ENZ annual total assets is $85.76 million

Annual Total Liabilities

$29.65 M
ENZ annual total liabilities is $29.65 million

Annual Cash & Cash Equivalents

$52.37 M
ENZ annual cash & cash equivalents is $52.37 million

Quarterly Accounts Receivable

$3.84 M
-$146.00 K-3.66%

October 31, 2024

Summary

Performance

3-Month Change

-3.66%

1-Year Change

-3.66%

3-Year Change

-66.1%

5-Year Change

-68.12%

ENZ Quarterly Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

35.47%
ENZ quarterly accounts receivable is higher than 35.47% of companies in Healthcare sector

High & Low

All-time High

$25.49 M
ENZ quarterly accounts receivable is currently -84.93% below its historical high of $25.49 million

3-Year Low

$3.84 M
ENZ quarterly accounts receivable is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Oct 31, 2024
ENZ previous earnings announcement was published on Oct 31, 2024

Next Quarterly Earnings Report Date

Mar 13, 2025
ENZ next earnings announcement is scheduled for Mar 13, 2025

OtherENZbalance sheetmetrics:

Quarterly Accounts Payable

$1.27 M
ENZ quarterly accounts payable is $1.27 million

Quarterly Total Assets

$75.29 M
ENZ quarterly total assets is $75.29 million

Quarterly Total Liabilities

$27.63 M
ENZ quarterly total liabilities is $27.63 million

Quarterly Cash And Cash Equivalents

$47.73 M
ENZ quarterly cash and cash equivalents is $47.73 million

Accounts Receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

ENZ Accounts Receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-17.1%-3.7%
3 y3 years-60.9%-66.1%
5 y5 years-62.9%-68.1%

ENZ Accounts Receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-60.9%at low-74.9%at low
5 y5-year-62.9%at low-74.9%at low
alltimeall time-83.8%at low-84.9%at low

Enzo Biochem Accounts Receivable History

DateAnnualQuarterly
Oct 2024
-
$3.84 M(-3.7%)
Jul 2024
$3.99 M(-17.1%)
$3.99 M(+1.3%)
Apr 2024
-
$3.94 M(-23.1%)
Jan 2024
-
$5.12 M(+22.4%)
Oct 2023
-
$4.18 M(-13.0%)
Jul 2023
$4.81 M(+1.0%)
$4.81 M(-50.1%)
Apr 2023
-
$9.64 M(-11.3%)
Jan 2023
-
$10.87 M(-5.6%)
Oct 2022
-
$11.52 M(+141.8%)
Jul 2022
$4.76 M(-53.3%)
$4.76 M(-59.5%)
Apr 2022
-
$11.76 M(-23.2%)
Jan 2022
-
$15.32 M(+35.2%)
Oct 2021
-
$11.33 M(+11.1%)
Jul 2021
$10.20 M(+11.6%)
$10.20 M(-11.1%)
Apr 2021
-
$11.47 M(-5.1%)
Jan 2021
-
$12.10 M(+0.4%)
Oct 2020
-
$12.05 M(+31.8%)
Jul 2020
$9.14 M(-14.9%)
$9.14 M(+34.1%)
Apr 2020
-
$6.82 M(-23.5%)
Jan 2020
-
$8.91 M(-9.8%)
Oct 2019
-
$9.88 M(-8.0%)
Jul 2019
$10.74 M(-18.3%)
$10.74 M(-6.1%)
Apr 2019
-
$11.44 M(-1.9%)
Jan 2019
-
$11.66 M(-9.1%)
Oct 2018
-
$12.84 M(-2.4%)
Jul 2018
$13.15 M(-13.4%)
$13.15 M(-8.7%)
Apr 2018
-
$14.41 M(-3.8%)
Jan 2018
-
$14.98 M(+3.7%)
Oct 2017
-
$14.44 M(-4.9%)
Jul 2017
$15.18 M(+4.0%)
$15.18 M(-4.0%)
Apr 2017
-
$15.80 M(+2.9%)
Jan 2017
-
$15.36 M(+9.2%)
Oct 2016
-
$14.06 M(-3.7%)
Jul 2016
$14.59 M(+20.5%)
$14.59 M(+4.2%)
Apr 2016
-
$14.00 M(+8.7%)
Jan 2016
-
$12.88 M(+0.9%)
Oct 2015
-
$12.76 M(+5.4%)
Jul 2015
$12.11 M(-2.9%)
$12.11 M(+4.3%)
Apr 2015
-
$11.61 M(-1.5%)
Jan 2015
-
$11.79 M(-4.7%)
Oct 2014
-
$12.38 M(-0.7%)
Jul 2014
$12.47 M(+1.5%)
$12.47 M(+1.3%)
Apr 2014
-
$12.31 M(+3.9%)
Jan 2014
-
$11.86 M(-13.6%)
Oct 2013
-
$13.72 M(+11.6%)
Jul 2013
$12.29 M
$12.29 M(-6.8%)
Apr 2013
-
$13.19 M(+4.8%)
Jan 2013
-
$12.58 M(-10.2%)
DateAnnualQuarterly
Oct 2012
-
$14.00 M(-0.9%)
Jul 2012
$14.13 M(-7.3%)
$14.13 M(+1.8%)
Apr 2012
-
$13.89 M(+3.6%)
Jan 2012
-
$13.40 M(-8.6%)
Oct 2011
-
$14.67 M(-3.8%)
Jul 2011
$15.24 M(+17.2%)
$15.24 M(+10.7%)
Apr 2011
-
$13.77 M(+9.7%)
Jan 2011
-
$12.55 M(-15.7%)
Oct 2010
-
$14.88 M(+14.4%)
Jul 2010
$13.01 M(+4.2%)
$13.01 M(+8.0%)
Apr 2010
-
$12.04 M(+0.3%)
Jan 2010
-
$12.01 M(-12.4%)
Oct 2009
-
$13.70 M(+9.8%)
Jul 2009
$12.48 M(-18.7%)
$12.48 M(+1.0%)
Apr 2009
-
$12.36 M(+11.8%)
Jan 2009
-
$11.05 M(-12.9%)
Oct 2008
-
$12.69 M(-17.3%)
Jul 2008
$15.35 M(+6.9%)
$15.35 M(+8.7%)
Apr 2008
-
$14.12 M(+4.7%)
Jan 2008
-
$13.49 M(-7.2%)
Oct 2007
-
$14.53 M(+1.3%)
Jul 2007
$14.35 M(+37.4%)
$14.35 M(+21.9%)
Apr 2007
-
$11.78 M(+14.9%)
Jan 2007
-
$10.25 M(+1.6%)
Oct 2006
-
$10.09 M(-3.4%)
Jul 2006
$10.45 M(-22.2%)
$10.45 M(-6.5%)
Apr 2006
-
$11.18 M(-4.1%)
Jan 2006
-
$11.65 M(-3.8%)
Oct 2005
-
$12.11 M(-9.7%)
Jul 2005
$13.42 M(-9.3%)
$13.42 M(-4.8%)
Apr 2005
-
$14.10 M(-4.0%)
Jan 2005
-
$14.68 M(+5.0%)
Oct 2004
-
$13.98 M(-5.5%)
Jul 2004
$14.79 M(-14.3%)
$14.79 M(-13.9%)
Apr 2004
-
$17.19 M(+0.7%)
Jan 2004
-
$17.07 M(+2.6%)
Oct 2003
-
$16.64 M(-3.6%)
Jul 2003
$17.27 M(-14.8%)
$17.27 M(-3.5%)
Apr 2003
-
$17.89 M(-11.1%)
Jan 2003
-
$20.11 M(-4.4%)
Oct 2002
-
$21.05 M(+3.9%)
Jul 2002
$20.27 M(-17.5%)
$20.27 M(-20.5%)
Apr 2002
-
$25.49 M(+7.8%)
Jan 2002
-
$23.65 M(-2.0%)
Oct 2001
-
$24.14 M(-1.7%)
Jul 2001
$24.56 M(+21.5%)
$24.56 M(+7.8%)
Apr 2001
-
$22.78 M(+9.5%)
Jan 2001
-
$20.81 M(+3.0%)
Jul 2000
$20.21 M
$20.21 M

FAQ

  • What is Enzo Biochem annual accounts receivable?
  • What is the all time high annual accounts receivable for Enzo Biochem?
  • What is Enzo Biochem annual accounts receivable year-on-year change?
  • What is Enzo Biochem quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Enzo Biochem?
  • What is Enzo Biochem quarterly accounts receivable year-on-year change?

What is Enzo Biochem annual accounts receivable?

The current annual accounts receivable of ENZ is $3.99 M

What is the all time high annual accounts receivable for Enzo Biochem?

Enzo Biochem all-time high annual accounts receivable is $24.56 M

What is Enzo Biochem annual accounts receivable year-on-year change?

Over the past year, ENZ annual accounts receivable has changed by -$820.00 K (-17.05%)

What is Enzo Biochem quarterly accounts receivable?

The current quarterly accounts receivable of ENZ is $3.84 M

What is the all time high quarterly accounts receivable for Enzo Biochem?

Enzo Biochem all-time high quarterly accounts receivable is $25.49 M

What is Enzo Biochem quarterly accounts receivable year-on-year change?

Over the past year, ENZ quarterly accounts receivable has changed by -$146.00 K (-3.66%)